Scarica l'app Stockscreener
86.29
2.08%
-1.83
Pre-mercato:
86.52
0.23
+0.27%
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approval Expands Obesity Treatment Reach - Sahm
Rhythm Pharmaceuticals (RYTM) reports phase 3 EMANATE trial topline results for setmelanotide - MSN
Rhythm Pharma down after late-stage trial setback for lead asset in rare obesity disorders - MSN
How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments - Yahoo Finance
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance Singapore
Rhythm Pharmaceuticals Setmelanotide FDA Approval, Company Details, and XBRL Filing Information - Minichart
Rhythm Pharmaceuticals Announces Changes to Board of Directors - Sahm
Rhythm Pharmaceuticals (RYTM) EVP converts RSUs, now holding 66,030 shares - Stock Titan
RHYTHM (RYTM) director receives 6,808 RSUs and 10,257 stock options - Stock Titan
Rhythm Pharmaceuticals (RYTM) director Kimberly Popovits files initial Form 3 - Stock Titan
Rhythm Pharmaceuticals adds Kim Popovits to board of directors By Investing.com - Investing.com Canada
Kim Popovits joins Rhythm (NASDAQ: RYTM) board as Ed Mathers exits - Stock Titan
Rhythm Pharmaceuticals, Inc. Announces Changes in Board of Directors - MarketScreener
Rhythm Pharmaceuticals adds Kim Popovits to board of directors - Investing.com
Rhythm Pharmaceuticals Announces Appointment of Kim Popovits as Director and Departure of Ed Mathers - Quiver Quantitative
Hennion & Walsh Asset Management Inc. Trims Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Strength seen in Rhythm Pharmaceuticals (RYTM): Can its 12.6% jump turn into more strength? - MSN
Rhythm posts first FDA approval for acquired hypothalamic obesity - Longevity.Technology
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength? - qz.com
Rhythm Pharma higher after FDA label expansion for lead drug - MSN
Rhythm Pharmaceuticals: Imcivree FDA Approval & Market Growth in 2025News and Statistics - IndexBox
Rhythm Pharma wins EU backing to expand Imcivree label - MSN
Discipline and Rules-Based Execution in RYTM Response - Stock Traders Daily
RYTM PE Ratio & Valuation, Is RYTM Overvalued - Intellectia AI
Rhythm Pharmaceuticals’ Stock Jumps After New Drug Approval - timothysykes.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading 10.9% HigherShould You Buy? - MarketBeat
Rhythm Pharmaceuticals Surges After FDA Approval for Obesity Treatment - StocksToTrade
Jefferies Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $125 - Moomoo
FDA’s Approval Sparks Optimism for Rhythm Pharmaceuticals - StocksToTrade
-7.42% for Rhythm Pharmaceuticals stock as sellers dominate near key support - Traders Union
Rhythm Pharmaceuticals (RYTM) Is Down 13.3% After EMA Backs IMCIVREE Label Expansion for Hypothalamic Obesity - Sahm
Vanguard disaggregates holdings; reports 0 shares in Rhythm Pharmaceuticals (NASDAQ: RYTM) - Stock Titan
Rhythm pharma down as FDA extends review period for Imcivree label expansion - MSN
Goldman Sachs Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $158 - Moomoo
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $105 - Moomoo
Rhythm Pharmaceuticals Gains EMA Backing for IMCIVREE Expansion - TipRanks
[8-K] RHYTHM PHARMACEUTICALS, INC. Reports Material Event - Stock Titan
Leerink reiterates Rhythm Pharmaceuticals stock rating on CHMP opinion By Investing.com - Investing.com Canada
Rhythm grabs a new obesity approval; how it edged in where Lilly, Novo have fallen flat - msn.com
Short Squeeze: What is the earnings history of Rhythm Pharmaceuticals IncWeekly Trend Summary & Fast Gain Swing Alerts - baoquankhu1.vn
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for - GlobeNewswire
EU panel backs Rhythm drug for obesity and hunger after brain injury - Stock Titan
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment - bitget.com
TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic ObesitySlideshow (NASDAQ:RYTM) 2026-03-24 - Seeking Alpha
TD Cowen reiterates Buy on Rhythm Pharmaceuticals stock at $130 - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
RYTM: HC Wainwright & Co. Maintains 'Buy' Rating, Raises Price T - GuruFocus
H.C. Wainwright raises Rhythm Pharmaceuticals stock price target on FDA approval - Investing.com Canada
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):